• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

设计并合成具有口服活性的喹啉吡嗪酰胺类 Sigma 2 受体配体,用于治疗胰腺癌。

Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer.

机构信息

Departments of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, North Campus Research Complex, 1600 Huron Parkway, Ann Arbor, Michigan 48109, United States.

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

出版信息

J Med Chem. 2023 Feb 9;66(3):1990-2019. doi: 10.1021/acs.jmedchem.2c01769. Epub 2023 Jan 24.

DOI:10.1021/acs.jmedchem.2c01769
PMID:36692906
Abstract

Sigma 2 receptor (σ2R) is overexpressed in select cancers and is regarded as a biomarker for tumor proliferation. σ2R ligands are emerging as promising theranostics for cancer and neurodegenerative diseases. Herein, we describe the design and synthesis of a series of novel quinolyl pyrazinamides as selective and potent σ2R ligands that show sub-micromolar potency in pancreatic cancer cell lines. Compounds (JR1-157) and (JR2-298) bind σ2R with of 47 and 10 nM, respectively. Importantly, compound has an oral bioavailability of 60% and shows significant in vivo efficacy without obvious toxicity in a syngeneic model of pancreatic cancer. The cytotoxicity of the quinolyl pyrazinamides significantly enhanced in the presence of copper and diminished in the presence of the copper-chelator tetrathiomolybdate. In conclusion, compound is water-soluble, metabolically stable, orally active, and increases the expression of the autophagy marker LC3B and warrants further development for the treatment of pancreatic cancer.

摘要

西格玛 2 受体(σ2R)在某些癌症中过度表达,被认为是肿瘤增殖的生物标志物。σ2R 配体作为癌症和神经退行性疾病的有前途的治疗方法正在出现。本文描述了一系列新型喹啉吡嗪酰胺的设计和合成,这些化合物是选择性和有效的 σ2R 配体,在胰腺癌细胞系中表现出亚微摩尔的效力。化合物 (JR1-157) 和 (JR2-298) 分别与 σ2R 的结合亲和力为 47 和 10 nM。重要的是,化合物 的口服生物利用度为 60%,在胰腺癌的同基因模型中显示出显著的体内疗效,且无明显毒性。在铜存在的情况下,喹啉吡嗪酰胺的细胞毒性显著增强,而在铜螯合剂四硫钼酸盐存在的情况下则减弱。总之,化合物 水溶性好、代谢稳定、口服活性强,并能增加自噬标志物 LC3B 的表达,值得进一步开发用于治疗胰腺癌。

相似文献

1
Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer.设计并合成具有口服活性的喹啉吡嗪酰胺类 Sigma 2 受体配体,用于治疗胰腺癌。
J Med Chem. 2023 Feb 9;66(3):1990-2019. doi: 10.1021/acs.jmedchem.2c01769. Epub 2023 Jan 24.
2
Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer.铜-KRAS-COX2轴:胰腺癌的一个治疗弱点。
J Med Chem. 2025 Apr 24;68(8):8400-8428. doi: 10.1021/acs.jmedchem.4c03159. Epub 2025 Mar 26.
3
Synthesis, binding, and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective σR/TMEM97 ligands.四氢异喹啉-2-烷基苯酮作为选择性 σR/TMEM97 配体的合成、结合和功能性质。
Eur J Med Chem. 2021 Jan 1;209:112906. doi: 10.1016/j.ejmech.2020.112906. Epub 2020 Oct 7.
4
Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.选择性σ-2配体优先结合胰腺腺癌:在诊断成像和治疗中的应用。
Mol Cancer. 2007 Jul 15;6:48. doi: 10.1186/1476-4598-6-48.
5
Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer.1-环己基-4-[3-(5-甲氧基-1,2,3,4-四氢萘-1-基)丙基]哌嗪(PB28)的西格玛-2受体激动剂衍生物通过胰腺癌中线粒体超氧化物的产生和半胱天冬酶激活诱导细胞死亡。
BMC Cancer. 2017 Jan 13;17(1):51. doi: 10.1186/s12885-016-3040-4.
6
Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.溶酶体膜通透性增加是 Sigma-2 受体配体介导的胰腺癌细胞死亡的早期事件。
J Exp Clin Cancer Res. 2012 May 2;31(1):41. doi: 10.1186/1756-9966-31-41.
7
Structure-affinity relationships of stereoisomers of norbenzomorphan-derived σR/TMEM97 modulators.苯并吗啡烷衍生的 σR/TMEM97 调节剂立体异构体的结构-亲和力关系。
Eur J Med Chem. 2023 Sep 5;257:115488. doi: 10.1016/j.ejmech.2023.115488. Epub 2023 May 23.
8
Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.利用 sigma-2 配体治疗胰腺癌。
Surgery. 2012 Sep;152(3 Suppl 1):S152-6. doi: 10.1016/j.surg.2012.05.014. Epub 2012 Jul 3.
9
Targeting σR/TMEM97 with novel aminotetralins.靶向 σR/TMEM97 的新型氨基四氢萘。
Eur J Med Chem. 2022 Dec 5;243:114696. doi: 10.1016/j.ejmech.2022.114696. Epub 2022 Aug 28.
10
Structure-activity relationships of mixed σR/σR ligands with antiproliferative and anticancer effects.具有抗增殖和抗癌作用的混合 σR/σR 配体的构效关系。
Bioorg Med Chem. 2022 Nov 1;73:117032. doi: 10.1016/j.bmc.2022.117032. Epub 2022 Sep 26.

引用本文的文献

1
Recent Advances in the Development of Sigma Receptor (Radio)Ligands and Their Application in Tumors.σ受体(放射性)配体的开发进展及其在肿瘤中的应用
ACS Pharmacol Transl Sci. 2025 Mar 7;8(4):951-977. doi: 10.1021/acsptsci.4c00711. eCollection 2025 Apr 11.
2
Pyrazine derivative synthesis in a continuous-flow system: a green synthesis of pyrazinamide from pyrazine esters and amines catalyzed by Lipozyme® TL IM from .连续流体系中吡嗪衍生物的合成:由源自......的Lipozyme® TL IM催化吡嗪酯和胺类进行绿色合成吡嗪酰胺
RSC Adv. 2024 Dec 16;14(53):39560-39568. doi: 10.1039/d4ra06761d. eCollection 2024 Dec 10.
3

本文引用的文献

1
Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.新型喹啉-8-基烟酰胺 QN523 诱导胰腺癌中应激反应和自噬相关基因的表达。
J Med Chem. 2022 Apr 28;65(8):6133-6156. doi: 10.1021/acs.jmedchem.1c02207. Epub 2022 Apr 19.
2
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
3
Structures of the σ receptor enable docking for bioactive ligand discovery.σ受体的结构有助于对接以发现生物活性配体。
Quinoline as a Privileged Structure: A Recent Update on Synthesis and Biological Activities.
喹啉作为一种优势结构:合成与生物活性的最新研究进展。
Curr Top Med Chem. 2024;24(27):2377-2419. doi: 10.2174/0115680266314303240830074056.
4
Trace elements in pancreatic cancer.胰腺癌中的微量元素
Cancer Med. 2024 Jul;13(14):e7454. doi: 10.1002/cam4.7454.
Nature. 2021 Dec;600(7890):759-764. doi: 10.1038/s41586-021-04175-x. Epub 2021 Dec 8.
4
Connecting copper and cancer: from transition metal signalling to metalloplasia.连接铜与癌症:从过渡金属信号到金属瘤形成。
Nat Rev Cancer. 2022 Feb;22(2):102-113. doi: 10.1038/s41568-021-00417-2. Epub 2021 Nov 11.
5
Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.将双硫仑及其衍生物重新用作铜依赖性抗癌药物的最新进展
Front Mol Biosci. 2021 Sep 17;8:741316. doi: 10.3389/fmolb.2021.741316. eCollection 2021.
6
Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models.靶向 sigma 受体的多功能硫代缩氨基脲:在胰腺癌模型中的体外和体内抗肿瘤活性。
Cell Oncol (Dordr). 2021 Dec;44(6):1307-1323. doi: 10.1007/s13402-021-00638-5. Epub 2021 Sep 29.
7
Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance.调节细胞内铜水平作为抗癌铜配合物的作用机制:临床相关性
Biomedicines. 2021 Jul 21;9(8):852. doi: 10.3390/biomedicines9080852.
8
σ Receptor and Its Role in Cancer with Focus on a MultiTarget Directed Ligand (MTDL) Approach.σ 受体及其在癌症中的作用,重点介绍一种多靶点定向配体 (MTDL) 方法。
Molecules. 2021 Jun 19;26(12):3743. doi: 10.3390/molecules26123743.
9
Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective.近年来,作为细胞毒剂的 sigma 受体配体的发展进展:药物化学视角。
J Med Chem. 2021 Jun 24;64(12):7926-7962. doi: 10.1021/acs.jmedchem.0c02265. Epub 2021 Jun 2.
10
Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms.氯喹和羟氯喹在基于自噬相关机制的抗肿瘤治疗中的应用。
Pharmacol Res. 2021 Jun;168:105582. doi: 10.1016/j.phrs.2021.105582. Epub 2021 Mar 26.